Partnering is proliferating among biopharma companies and service providers in the effort to increase quality and effectiveness in clinical trials. This week, ASAP officially announced that INC Research Holdings, Inc. (Nasdaq: INCR), a leading global contract research organization (CRO), has joined the ranks of ASAP as a global member. Judy Swilley, executive vice president and head of INC Research’s strategic alliance team, will represent INC as a new member of the ASAP board.
“We are thrilled to have INC Research on board as a Global Member and look forward to its team’s deep engagement and rich contributions to the ASAP community of practice,” commented Michael Leonetti, CSAP, president and CEO of ASAP, in the ASAP press release.
Leonetti also noted that “INC Research has built an amazing reputation as a customer- and partner-centric company, and this year was ranked as the top CRO to work with among global CROs.” The company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey.
“Joining ASAP in a leadership role is another way INC is working to become CRO of choice for our biopharmaceutical customers,” said Swilley in the announcement. “By strategically expanding our alliances in clinical development we can continue to enhance INC’s reputation for delivering timely, trusted, high-quality results to our customers, which then more swiftly delivers needed medicines to market.”
INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. The CRO provides a full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging its service offerings and therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market.
Read the complete press release distributed via PR Web at http://www.prweb.com/releases/2015/12/prweb13115676.htm .